Re: Not just another data point - get a picture of his email
Get a grip, people. Trodlevy, which Feuerstein inquires about, got accelerated, conditional approval for TNBC. From the Immunomedics website:
`"TRODELVY (sacituzumab govitecan-hziy) is a Trop-2 directed antibody-drug conjugate indicated for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials."
I'm not saying Feuerstein's motives are pure, or that it's even his business, but I suggest you look at the basis of your own interest in this case when Leronlimab doesn't have even conditional approval yet.